Emerging Outsourcing Trends in 2013 - BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing. - BioPharm International

ADVERTISEMENT

Emerging Outsourcing Trends in 2013
BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.


BioPharm International Supplements
Volume 26, Issue 3, pp. s4-s7

OUTLOOK

The continued rise in outsourcing suggests that product manufacturers are tending to view contract manufacturing and outsourced services more as an asset to drive strategic decisions than as simply a way to save money. Some companies have also become more comfortable letting go of some of their more crucial activities, and have become more trusting of CMOs.

Careful selection of an effective CMO with the requisite know-how and observation of industry standards and process can increase the value of outsourcing, and potentially mitigate risks of outsourcing high-level activities. Biopharma CMOs are expanding their manufacturing competence through the use of novel technologies, single-use/disposable bioreactors, and other differentiated bioprocessing services. Expansions are resulting in increased adaptability, lower costs, faster turnaround, and higher yields.

For clients, this means that more CMOs will likely meet their needs (more competition, more choice), and the costs for using CMOs for product manufacturing are becoming at least slightly more competitive. Biologics manufacturing is inherently complex, and companies are becoming more aware of the value of experienced CMOs as a provider of expertise, as well as a back-up manufacturer, with 'flex' capacity.

Outsourcing of biopharmaceutical manufacture is a long-term trend.


Survey Methodology
Outsourcing of biopharmaceutical manufacture is a long-term trend that will require adoption of project management processes, and specific skills to manage external relationships. The industry and, particularly client-contractor relationships, will continue to mature and become more complex. With these changes will come a more cooperative management and maintenance of outsourcing relationships, which will increase the ability to partner on technically complex projects. We should expect to see more companies become confident outsourcing core activities in the future.

Eric S. Langer is president and managing partner at BioPlan Associates, Inc. Rockville, MD,
, tel. 301.921.5979, http://www.bioplanassociates.com.

REFERENCES

1. BioPlan, 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, Preliminary Data, Publication April 2013, Rockville, MD, http://www.bioplanassociates.com


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here